Black Diamond Therapeutics, Inc vs Merck & Company, Inc. — Stock Comparison

BDTX
Black Diamond Therapeutics, Inc
$2.60
▼ 1.89%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Black Diamond Therapeutics, Inc
BDTX8.3/10vs 6.7/10

Q·Score Breakdown

8.3
Bullish
Overall
6.7
Neutral
10
Quality
6.2
9.7
Health
7
6.5
Growth
6.2
6.9
Valuation
7.2
7.9
Sentiment
7.1
BDTX

High-quality business with 23% return on equity and 32% profit margins.

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $9.86 (+279.1%)
7 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

BDTX
MRK
6.7×
Trailing P/E
31.5×
-2.5×
Forward P/E
11.5×
32.0%
Profit Margin
13.6%
100.0%
Gross Margin
76.6%
22.9%
ROE
Revenue Growth
4.9%
Earnings Growth
3.39
Beta
0.28
Price / Book
$149M
Market Cap
$277.0B
$1 – $5
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →